AGP Wins 1st Position in Pharmaceutical Category at BCSR Awards 2024 — for the Second Consecutive Year!

AGP Celebrates Dual Recognition at the 8th Pakistan Pharma Summit & PESA Awards 2025

AGP Receives the 22nd Annual Environment Excellence Award 2025

AGP Wins GDEIB Awards in Nine Categories

AGP x TrashIt Sustainability Training

AGP x Cyber Security Awareness Training

AGP x Cancer Foundation Hospital: Breast Cancer Awareness Session

AGP Visits Karachi Down Syndrome Program (KDSP)

Diwali Celebration at AGP: Honoring Diversity, Culture & Togetherness

AGP Limited Secures 1st Position at BCSR Awards 2023

AGP collaborates with Childlife Foundation on Children’s Day 2023

AGP Launched Peridots – A Thanda Solution to Acidity, Gas and Indigestion

AGP secures 2nd Position at BCR Awards 2022

AGP wins Top Exporter Award at 6th PPMA Summit

AGP sponsors KDSP Carnival 2023

AGP bags big win at GDEIB Awards 2023

AGP continues partnership with IBA

AGP continues collaboration with TCF

AGP joins hands with SKMF

AGP continues partnership with ACF

AGP conducts Allergy Awareness Session At Pak Turk Maarif

Gong-Ringing Ceremony of AGP at PSX

Product List

TruGlif Met

Generic:

Empagliflozin, Metformin HCl
 

Therapeutic Class:

SGLT2 Inhibitors & Biguanide Combs

 

Composition:

  • TruGlif Met Tab 12.5 mg /500 mg: Each tablet contains 12.5 mg Empagliflozin and 500 mg Metformin HCl.
  • TruGlif Met Tab 12.5 mg /1000 mg: Each tablet contains 12.5 mg Empagliflozin and 1000 mg Metformin HCl.
 

Description:

TruGlif Met (Empagliflozin and metformin) is used with proper diet and exercise to treat high blood sugar levels caused by type 2 diabetes.

 

Indications:

TruGlif Met is indicated for the treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise:

 

• In patients insufficiently controlled on their maximally tolerated dose of metformin alone

• In combination with other medicinal products for the treatment of diabetes, in patients insufficiently controlled with metformin and these medicinal products

• In patients already being treated with the combination of empagliflozin and metformin as separate tablets.

Dosage:

The maximum recommended dose is 12.5 mg empagliflozin and 1000 mg metformin HCl twice daily. Take twice daily with meals, with gradual dose escalation to reduce the gastrointestinal side effects due to metformin.

 

  • Adults with normal renal function (GFR ≥90 ml/min)

The recommended dose is one tablet twice daily. The dosage should be individualized on the basis of the patient’s current regimen, effectiveness, and tolerability using the recommended daily dose of 10 mg or 25 mg of empagliflozin, while not exceeding the maximum recommended daily dose of metformin.

 

  • For patients switching from separate tablets of empagliflozin and metformin

Patients switching from separate tablets of empagliflozin and metformin should receive the same daily dose of empagliflozin and metformin already being taken or the nearest therapeutically appropriate dose of metformin.

 

  • Renal impairment

Not recommended in patients with an eGFR less than 45 mL/min/1.73 m2, due to the metformin component

Presentations:

  • TruGlif Met Tablets 12.5 mg / 500 mg available in pack of 14’s.
  • TruGlif Met Tablets 12.5 mg /1000 mg available in pack of 14’s.